HK102894A - Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it - Google Patents

Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it Download PDF

Info

Publication number
HK102894A
HK102894A HK102894A HK102894A HK102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A
Authority
HK
Hong Kong
Prior art keywords
ciclosporin
crystal form
production
pharmaceutical compositions
orthorhombic
Prior art date
Application number
HK102894A
Other languages
English (en)
Inventor
Giron Danielle
List Martin
Richter Friedrich
Ulke Yasuyuki
Peter Weber Hans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK102894A publication Critical patent/HK102894A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK102894A 1987-12-21 1994-09-22 Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it HK102894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13623087A 1987-12-21 1987-12-21
US17261388A 1988-03-24 1988-03-24
US21254888A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
HK102894A true HK102894A (en) 1994-09-30

Family

ID=27384838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK102894A HK102894A (en) 1987-12-21 1994-09-22 Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it

Country Status (27)

Country Link
JP (1) JPH0791316B2 (it)
KR (1) KR100188305B1 (it)
AT (1) AT403163B (it)
AU (1) AU626274B2 (it)
BE (1) BE1002665A4 (it)
CA (1) CA1341396C (it)
CH (1) CH677926A5 (it)
CY (1) CY1799A (it)
DE (1) DE3843054C2 (it)
DK (1) DK175220B1 (it)
ES (1) ES2012580A6 (it)
FI (1) FI89065C (it)
FR (1) FR2624863B1 (it)
GB (1) GB2211848B (it)
GR (1) GR1002486B (it)
HK (1) HK102894A (it)
HU (1) HU203564B (it)
IE (1) IE62006B1 (it)
IL (1) IL88719A0 (it)
IT (1) IT1235356B (it)
LU (1) LU87409A1 (it)
MY (1) MY103943A (it)
NL (1) NL195096C (it)
NO (1) NO177228C (it)
NZ (1) NZ227384A (it)
SE (1) SE503174C2 (it)
SG (1) SG99494G (it)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
DE69307505T2 (de) * 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
EP1142568A1 (en) 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
AU715165B2 (en) 1994-11-03 2000-01-20 Novartis Ag Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
US6262054B1 (en) 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
EP1331002A3 (en) 1997-01-30 2004-01-14 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin A
TW581681B (en) 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN1763084B (zh) * 2005-10-11 2010-04-21 山东新时代药业有限公司 高纯度环孢菌素a的制备方法
CA2836946C (en) 2011-05-27 2017-08-01 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
RU2630970C2 (ru) * 2011-11-15 2017-09-15 Аллерган, Инк. Автоклавируемые взвеси циклоспорина а формы 2
ES2666191T3 (es) * 2011-11-15 2018-05-03 Allergan, Inc. Un proceso para la cristalización de la forma 2 de la ciclosporina A
RU2639393C2 (ru) 2011-11-15 2017-12-21 Аллерган, Инк. Состав пролонгированного действия циклоспорина формы 2
JP6363506B2 (ja) 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
EP4585605A1 (en) * 2022-10-20 2025-07-16 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (it) * 1975-11-04 1979-12-28 Sandoz Ag
CH640519A5 (en) * 1976-04-09 1984-01-13 Sandoz Ag Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
CH637124A5 (en) * 1978-10-18 1983-07-15 Sandoz Ag Antibiotic, its preparation and use

Also Published As

Publication number Publication date
IE883779L (en) 1989-06-21
GB2211848A (en) 1989-07-12
NZ227384A (en) 1991-09-25
IL88719A0 (en) 1989-07-31
NL8803125A (nl) 1989-07-17
IT1235356B (it) 1992-06-30
CH677926A5 (it) 1991-07-15
SE8804570D0 (sv) 1988-12-19
MY103943A (en) 1993-10-30
NO177228B (no) 1995-05-02
ES2012580A6 (es) 1990-04-01
FR2624863A1 (fr) 1989-06-23
KR100188305B1 (ko) 1999-06-01
DE3843054A1 (de) 1989-07-27
CA1341396C (en) 2002-11-05
JPH01211598A (ja) 1989-08-24
DK705488D0 (da) 1988-12-19
NL195096C (nl) 2004-02-09
HUT49893A (en) 1989-11-28
GB8829556D0 (en) 1989-02-08
KR890009975A (ko) 1989-08-05
DE3843054C2 (de) 2003-08-21
AU2705588A (en) 1989-06-22
GR1002486B (el) 1996-12-09
HU203564B (en) 1991-08-28
GB2211848B (en) 1991-11-06
JPH0791316B2 (ja) 1995-10-04
DK175220B1 (da) 2004-07-12
FI89065C (fi) 1993-09-30
FR2624863B1 (fr) 1991-04-26
AU626274B2 (en) 1992-07-30
NO885625L (no) 1989-06-22
BE1002665A4 (fr) 1991-04-30
IE62006B1 (en) 1994-12-14
SE8804570L (sv) 1989-06-22
FI885869L (fi) 1989-06-22
FI89065B (fi) 1993-04-30
GR880100850A (el) 1994-03-31
SE503174C2 (sv) 1996-04-15
SG99494G (en) 1994-10-28
CY1799A (en) 1995-02-17
NO177228C (no) 1995-08-09
ATA309588A (de) 1997-04-15
AT403163B (de) 1997-11-25
FI885869A0 (fi) 1988-12-19
LU87409A1 (fr) 1989-07-07
DK705488A (da) 1989-06-22
NO885625D0 (no) 1988-12-19
IT8848690A0 (it) 1988-12-20

Similar Documents

Publication Publication Date Title
HK102894A (en) Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it
IE891798L (en) Novel ó-glucosidase inhibitors
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
EP0142426A3 (en) Ophthalmic formulation containing norfloxacin and related antibiotics
EP0374440A3 (en) Inhibitors of lysyl oxidase
EG18379A (en) Novel pharmacological compounds
ES479474A1 (es) Procedimiento para la obtencion de una composicion a base dederivados de la piridina de accion cerebral.
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
HU9502588D0 (en) Heterocyclic compounds and their preparation and use
EP1167354A3 (en) Racemic huperzine A
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
WO1996022305A3 (en) Modified peptides
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
MY107449A (en) Bcrf1 proteins as inhibitors of interferon- gamma.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
HUT46660A (en) Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient
CA2047802A1 (en) Pharmaceutical compositions
EP0378413A3 (en) Compositions for topical treatment of skin disorders
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
IE870577L (en) Topical amide preparation
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
ES447307A1 (es) Procedimiento para la preparacion de una 1-(alfa-sustituida--aminoacil)-3-desoxirribostamicina.
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
AU3577589A (en) Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20081218